| MUC1 alters oncogenic events and transcription in human breast cancer cells. | breast, |
| MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. | thyroid, |
| MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. | leukemia, |
| Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. | breast, |
| MUC1 oncoprotein is a druggable target in human prostate cancer cells. | prostate, |
| Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. | breast, |
| Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. | leukemia, |
| MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. | breast, |
| This study signifies the oncogenic role of MUC1 cytoplasmic tail and is the first to identify a direct role of the MUC1 in initiating EMT during pancreatic cancer. | pancreatic, |
| Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells. | prostate, |
| Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. | lung, |
| MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. | leukemia, |
| MUC1-C Oncoprotein Blocks Terminal Differentiation of Chronic Myelogenous Leukemia Cells by a ROS-Mediated Mechanism. | leukemia, |
| MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells. | breast, |
| MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. | prostate, |
| MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. | breast, |
| Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. | breast, |
| Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells. | breast, |
| Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer. | breast, |
| Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. | breast, |